ASCO Career Center ASCO Connection

Forty-three patients (52%) had node-positive disease, with similar node-positive rates for type I (n = 21, 51.2%) and type II (n = 22, 52.4%). When combined with a taxane, platinum agents improve response in metastatic breast cancer, with carboplatin conferring less toxicity than cisplatin. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Hoskins PJ, Swenerton KD, Pike JA, et al. The investigators hypothesize that the combination of weekly Abraxane® and carboplatin will lengthen time to progression without producing intolerable toxicity. P30 CA016359/CA/NCI NIH HHS/United States. Epub 2018 Oct 2. 2015 Aug. 76 (2):335-42. . The New England Journal of Medicine recently published the primary endpoint of the NRG Oncology clinical trial NRG-GOG 0258, which showed that carboplatin and paclitaxel chemotherapy preceded by radiotherapy with concurrent cisplatin, or combined modality therapy, did not significantly increase recurrence-free survival for women with stage 3-4A endometrial cancer when compared to chemotherapy with carboplatin and paclitaxel alone. These results were also presented in abstract form at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Patients with third degree or complete heart block are not eligible unless a pacemaker is in place. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02744898. Laboratory tests performed within 14 days of study entry showing: To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Stay up to date with our ecancer newsletter, Explore patient resources at ecancerpatient, Find out more about ecancer and the work we do, Support ecancer's work by making a donation, The content on this site is intended for healthcare professionals only, ESMO 2020: KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial, Researchers now better understand ovarian cancer tumours and treatment outcomes, Researchers discover how enzyme protects cells from DNA damage, A new way to target cancers using 'synthetic lethality', ASCO 2020: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumours, ASCO 2020: Immunotherapy avelumab shows potential in rare gynaecological cancer resistant to chemotherapy, New targeted agent produces considerable responses in patients with uterine cancer, Drug overcomes chemotherapy resistance in ovarian cancer, FDA approves mitomycin for low-grade upper tract urothelial cancer, Therapeutic HPV vaccine may improve outcomes in advanced cervical cancer. 4 cases of more than Grade 3 neutropenia were found and 2 cases of more than grade 3 thrombocytopenia and 4 cases needed blood transfusion. Advertisers, Journal of Clinical Oncology

ASCO Daily News

JCO OP DAiS, ASCO eLearning Epub 2012 Jul 28. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. 22 patients enrolled. Kaplan Meier methods were used to calculate estimated 3 year DFS and OS. Franco M. Muggia, Chat with us: LiveHelp The single stage open label Phase II feasibility study is designed to estimate the proportion of patients who can tolerate the proposed regimen for 6 cycles with no more than two dose level reductions. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Talk with your doctor and family members or friends about deciding to join a study.

Li JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. J Gynecol Oncol. 2009 Oct;115(1):6-11. doi: 10.1016/j.ygyno.2009.06.035. Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle, Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days, Other Name: paclitaxel protein-bound particles for injectable suspension, area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days.